Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2019-06-17
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TODAY Genetics Study
NCT00722397
Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk
NCT01727349
The Next Generation Longitudinal Birth Cohort Diabetes Study
NCT04621396
Pedometers for Gestational Diabetes
NCT00862602
Relationship Between Gestational Diabetes and Type 2 Diabetes
NCT01340924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phenotyping
All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.
They will also undergo a whole body DXA (intervention) during the study day.
75g glucose beverage (Glucola, Trutol, or similar brand)
Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
DXA, whole body
Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
75g glucose beverage (Glucola, Trutol, or similar brand)
Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
DXA, whole body
Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research.
* Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher
Exclusion Criteria
* use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication
* acute illness that may impact insulin and glucose dynamics
* pregnancy
* hypothalamic obesity or related genetic disorder of metabolism
* recent systemic chemotherapy use
* gastrointestinal impairment or surgery that may impact absorption
* anemia
* major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult
* inability to comply with study protocol
10 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jessica R.Wilson, MD, MS
Instructor in Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica R Wilson, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Lorraine Levitt Katz, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital of Philadelphia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
831865
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.